Efficacy

No RCTs were found. Interleukin (IL)-2 (20 MU/m2 every 2 weeks for 6 weeks and then monthly for 5 months) produced responses in five of seven CTCL patients, including CR in three.40

In a phase I dose-escalation study of subcutaneous IL-12 (50-300 ng/kg) twice weekly for up to 24 weeks, objective responses were noted in five CTCL patients (4/5 with stage IB disease; 1/3 with Sezary syndrome).41 Two patients with stage IB disease had a CR within 7-8 weeks, which was confirmed histologically. Intralesional therapy was also effective for individual tumours in two patients with stage IIB disease, but both developed progressive disease.41

0 0

Post a comment